期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 103, 期 -, 页码 202-217出版社
ELSEVIER
DOI: 10.1016/j.addr.2016.02.008
关键词
Anti-retroviral (ARV) therapy; Nanotechnology; HIV-1; Blood-brain barrier (BBB); CNS drug delivery; NeuroAIDS; Magnetic nanoparticle; HIV monitoring
资金
- NIH [R01-DA037838, RO1-DA034547, R21-MH 101025, RO1-DA027049, 1R01-DA-040537]
In spite of significant advances in antiretroviral (ARV) therapy, the elimination of human immunodeficiency virus (HIV) reservoirs from the periphery and the central nervous system (CNS) remains a formidable task. The incapability of ARV to go across the blood-brain barrier (BBB) after systemic administration makes the brain one of the dominant HIV reservoirs. Thus, screening, monitoring, and elimination of HIV reservoirs from the brain remain a clinically daunting and key task. The practice and investigation of nanomedicine possesses potentials for therapeutics against neuroAIDS. This review highlights the advancements in nanoscience and nanotechnology to design and develop specific size therapeutic cargo for efficient navigation across BBB so as to recognize and eradicate HIV brain reservoirs. Different navigation and drug release strategies, their biocompatibility and efficacy with related challenges and future prospects are also discussed. This review would be an excellent platform to understand nano-enable multidisciplinary research to formulate efficient nanomedicine for the management of neuroAIDS. (C) 2016 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据